Is valsartan renoprotective in patients with IgA nephropathy?
Li PK et al. (2006) Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751–760 Synopsis Background The putative renal benefit of angiotensin-receptor blockers (ARBs) in IgA nephropathy requires confirmation in a prospective, controlled setting.